Journal ArticleDOI
Circulating serum miRNAs as potential biomarkers for nephroblastoma
Nicole Ludwig,Nasenien Nourkami-Tutdibi,Christina Backes,Hans-Peter Lenhof,Norbert Graf,Andreas Keller,Eckart Meese +6 more
TLDR
Preoperative chemotherapy without histological confirmation by biopsy without minimal‐invasive diagnostic markers confirming nephroblastoma diagnosis are highly warranted.Abstract:
Background
Nephroblastoma (or Wilms tumor—WT) is the most common childhood kidney cancer. In Europe, nephroblastoma is treated with preoperative chemotherapy without histological confirmation by biopsy. Therefore, minimal-invasive diagnostic markers confirming nephroblastoma diagnosis are highly warranted.
Procedure
In our study, we aim to identify circulating miRNAs with diagnostic potential for differentiating nephroblastoma from controls. We determined the level of 19 miRNAs in serum of 32 patients with nephroblastoma and 12 controls with quantitative real-time PCR. Three miRNAs were further tested in an independent validation set including sera of patients with renal tumors other than Wilms.
Results
In total, 14 miRNAs showed significantly higher abundance in serum of patients with nephroblastoma than in controls. The miRNAs with highest diagnostic potentials included miRs-130b-3p, -100-5p, and -143-3p with an AUC of 0.94, 0.90, and 0.89, respectively. A signature based on these three miRNAs to differentiated patients from controls with an accuracy of 84.58%, a sensitivity of 76.67%, and a specificity of 92.5%. Higher expression of miRs-100-5p and -130b-3p was confirmed in an independent validation set. The signature based on miRs-100-5p and -130b-3p differentiated patients with nephroblastoma from healthy controls with an accuracy, sensitivity, and specificity of 79.6%, 69.2%, and 90.0%, respectively.
Conclusion
In summary, we provide first evidence that serum miR-100-5p and -130b-3p hold potential as biomarker for WT irrespective of the subtype and that expression level of these miRNA in serum is unaffected by differences in serum collection. Pediatr Blood Cancer 2015;62:1360–1367. © 2015 Wiley Periodicals, Inc.read more
Citations
More filters
Journal ArticleDOI
An estimate of the total number of true human miRNAs.
Julia Alles,Tobias Fehlmann,Ulrike Fischer,Christina Backes,Galata,Marie Minet,Martin Hart,Masood Abu-Halima,Friedrich A. Grässer,Hans-Peter Lenhof,Andreas Keller,Eckart Meese +11 more
TL;DR: The experimentally validated miRNAs will contribute to revising targetomes hypothesized by utilizing falsely annotated miRNA candidates, 1115 of which are currently annotated in miRBase V22.
Journal ArticleDOI
A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours
Matthew J. Murray,Emma Bell,Emma Bell,Katie L. Raby,Martin A. Rijlaarsdam,Ad J. M. Gillis,Leendert H. J. Looijenga,Helen Brown,Benoit Destenaves,James Nicholson,Nicholas Coleman +10 more
TL;DR: A robust technical pipeline to quantify miRNAs in the serum and cerebrospinal fluid and allowed early detection of relapse of a testicular mixed malignant GCT; and distinguished intracranial malignantGCT from intrac Cranial non-GCT tumours at diagnosis, using CSF and serum samples are developed.
Journal ArticleDOI
The translational potential of microRNAs as biofluid markers of urological tumours
TL;DR: Qualitative and analytical pitfalls exist and require addressing to enable future translation of the laboratory findings regarding miRNAs as biomarkers into clinical practice in bladder cancer, kidney cancer, prostate cancer and testicular cancer.
Journal ArticleDOI
Biology and treatment of renal tumours in childhood.
Jesper Brok,Jesper Brok,Taryn D. Treger,Saskia L. Gooskens,Saskia L. Gooskens,Marry M. van den Heuvel-Eibrink,Kathy Pritchard-Jones +6 more
TL;DR: Ongoing collaboration is needed to ensure consistency of outcomes through standardised diagnostics and treatment and incorporation of biomarker research, which constitute the rationale for the forthcoming SIOP-RTSG 'UMBRELLA' study.
References
More filters
Journal ArticleDOI
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function
TL;DR: Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.
Journal ArticleDOI
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
TL;DR: It is shown here that miRNAs are present in human plasma in a remarkably stable form that is protected from endogenous RNase activity and established the measurement of tumor-derived mi RNAs in serum or plasma as an important approach for the blood-based detection of human cancer.
Journal ArticleDOI
Assessing sample and miRNA profile quality in serum and plasma or other biofluids
Thorarinn Blondal,Søren Jensby Nielsen,Adam Baker,Ditte Andreasen,Peter Mouritzen,Maria Wrang Teilum,Ina K. Dahlsveen +6 more
TL;DR: Normal reference ranges for circulating miRNAs in serum and plasma as well as a hemolysis indicator based on microRNA expression are developed.
Journal ArticleDOI
Haemolysis during sample preparation alters microRNA content of plasma.
Michaela B. Kirschner,Steven Kao,Steven Kao,J. James B. Edelman,Nicola J. Armstrong,Michael P. Vallely,Nico van Zandwijk,Glen Reid +7 more
TL;DR: It is found that levels of miR-16, a commonly used reference gene, showed little variation when measured in plasma samples from healthy volunteers or patients with malignant mesothelioma or coronary artery disease, and increases in plasma miR -16 andMiR-451 are caused by haemolysis.
Related Papers (5)
Circulating microRNAs as stable blood-based markers for cancer detection
Patrick S. Mitchell,Rachael K. Parkin,Evan M. Kroh,Brian R. Fritz,Brian R. Fritz,Stacia K. Wyman,Era L. Pogosova-Agadjanyan,Amelia Peterson,Jennifer Noteboom,Kathy O'Briant,April Allen,Daniel W. Lin,Daniel W. Lin,Daniel W. Lin,Nicole Urban,Charles W. Drescher,Beatrice S. Knudsen,Derek L. Stirewalt,Robert Gentleman,Robert L. Vessella,Robert L. Vessella,Peter S. Nelson,Daniel Martin,Daniel Martin,Muneesh Tewari +24 more
Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors
Jenny Wegert,Naveed Ishaque,Romina Vardapour,Christina Geörg,Zuguang Gu,Matthias Bieg,Barbara Ziegler,Sabrina Bausenwein,N. Nourkami,Nicole Ludwig,Andreas Keller,Clemens Grimm,Susanne Kneitz,Richard D. Williams,Tasnim Chagtai,Kathy Pritchard-Jones,Peter van Sluis,Richard Volckmann,Jan Koster,Rogier Versteeg,T Acha,Maureen J. O'Sullivan,Peter K. Bode,Felix Niggli,Godelieve A.M. Tytgat,Harm van Tinteren,Marry M. van den Heuvel-Eibrink,Eckart Meese,Christian Vokuhl,Ivo Leuschner,Norbert Graf,Roland Eils,Roland Eils,Stefan M. Pfister,Marcel Kool,Manfred Gessler +35 more